Actively Recruiting
Success Rates of Expectant vs. Medical Management for Retained Products After First-Trimester Abortion: Randomized Controlled Trial
Led by Yael Yagur · Updated on 2026-04-16
150
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
Y
Yael Yagur
Lead Sponsor
M
Meir Hospital, Kfar Saba, Israel
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective randomized controlled trial evaluates the success of medical versus expectant management for retained products of conception (RPOC) following medical abortion with mifepristone and misoprostol for delayed miscarriage in the first trimester. Women aged 18-45 with sonographic evidence of RPOC (endometrial thickness \>10 mm with Doppler flow) will be randomized into two groups: medical management with misoprostol or expectant management (observation only). Follow-up will include ultrasound evaluations over six weeks to monitor uterine clearance and determine further interventions. Population: 150 participants, with 75 in each group. Inclusion Criteria: Stable women with RPOC after medical abortion, bleeding comparable to menstrual flow, and no fever. Exclusion Criteria: Hemodynamic instability, excessive bleeding, fever, or specific endometrial thickness criteria. Outcome Measures: RPOC resolution, need for surgical intervention, complications, and sonographic changes. Study Duration: Five years. Data on demographics, medical history, and ultrasound findings will be analyzed using SPSS, with results informing optimal management strategies for RPOC after first-trimester medical abortion.
CONDITIONS
Official Title
Success Rates of Expectant vs. Medical Management for Retained Products After First-Trimester Abortion: Randomized Controlled Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 45 years
- Retained products of conception identified by ultrasound after medical abortion, defined as endometrial thickness greater than 10 mm with Doppler flow into the uterine cavity
- Hemodynamically stable with bleeding comparable to menstrual flow
- No fever present
You will not qualify if you...
- Hemodynamic instability, excessive bleeding, or fever
- Endometrial thickness greater than 40 mm
- Endometrial thickness less than 10 mm without Doppler flow into the cavity
- Presence of a gestational sac within the uterine cavity
- Receipt of two doses of misoprostol before evaluation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Meir Medical Center
Kfar Saba, Israel, 4861027
Actively Recruiting
Research Team
C
Chen Manor Bar, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here